HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freland, S. Articles by Ljunggren, H.-G. Search for Related Content PubMed PubMed Citation Articles by Freland, S. Articles by Ljunggren, H.-G.

Rejection of Allogeneic and Syngeneic But Not MHC Class I-Deficient Tumor Grafts by MHC Class I-Deficient Mice¹

Sofia Freland^*, Benedict J. Chambers^*, Malena Andersson^*, Luc Van Kaer and Hans-Gustaf Ljunggren^2,*

^* Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden; and Howard Hughes Medical Research Institute and Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232

The ability of TAP1^-/-, ß2m^-/-, and TAP1/ß2m^-/- mice to mount rejection responses against allogeneic, syngeneic, and MHC class I-deficient tumor grafts was examined. The results demonstrate a potent ability of TAP1^-/- and ß2m^-/- as well as TAP1/ß2m^-/- mice to reject allogeneic tumors. In contrast to published data, rejection of syngeneic MHC class I-expressing tumors was also observed. This response was specific for the MHC class I-deficient mice, since wild-type mice did not reject syngeneic MHC class I-positive tumors under identical experimental conditions. The rejection response of syngeneic tumors required preimmunization of the mice and was MHC class I specific at the level of priming as well as at the level of the tumor target. Finally, MHC class I-deficient tumor grafts were accepted in MHC class I-deficient mice while similar grafts were rejected in wild-type mice. In summary, while MHC class I-deficient mice have retained a capacity to reject allogeneic tumors, they have gained an ability to reject syngeneic MHC class I-positive tumors and lost the ability to reject MHC class I-negative tumors. The present results are discussed in relation to the role of MHC class I molecules in selecting functional CD8⁺ T and NK cell repertoires, and the development of cell-mediated immunity.

This article has been cited by other articles:

				E. Schott, R. Bonasio, and H. L. Ploegh Elimination In Vivo of Developing T Cells by Natural Killer Cells J. Exp. Med., October 20, 2003; 198(8): 1213 - 1224. [Abstract] [Full Text] [PDF]

				T. Hayashi and D. L. Faustman Role of Defective Apoptosis in Type 1 Diabetes and Other Autoimmune Diseases Recent Prog. Horm. Res., January 1, 2003; 58(1): 131 - 153. [Abstract] [Full Text] [PDF]

				T. D. Schell, L. M. Mylin, S. S. Tevethia, and S. Joyce The assembly of functional {beta}2-microglobulin-free MHC class I molecules that interact with peptides and CD8+ T lymphocytes Int. Immunol., July 1, 2002; 14(7): 775 - 782. [Abstract] [Full Text] [PDF]

				T. Hayashi and D. Faustman NOD Mice Are Defective in Proteasome Production and Activation of NF-kappa B Mol. Cell. Biol., December 1, 1999; 19(12): 8646 - 8659. [Abstract] [Full Text] [PDF]

				S. Korten, E. Wilk, J. E. Gessner, D. Meyer, and R. E. Schmidt Altered Donor and Recipient Ly49+ NK Cell Subsets in Allogeneic H-2d -> H-2b and H-2b -> H-2d Bone Marrow Chimeras J. Immunol., December 1, 1999; 163(11): 5896 - 5905. [Abstract] [Full Text] [PDF]